151. Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary.
- Author
-
Pouyiourou M, Wohlfromm T, Kraft B, Hielscher T, Stichel D, von Deimling A, Delorme S, Endris V, Neumann O, Stenzinger A, Krämer A, and Bochtler T
- Subjects
- Adult, Aged, Combined Modality Therapy, DNA Copy Number Variations, Female, Genes, p53, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasms, Unknown Primary genetics, Neoplasms, Unknown Primary mortality, Neoplasms, Unknown Primary pathology, Prognosis, Retrospective Studies, Neoplasms, Unknown Primary therapy
- Abstract
Background: Single-site carcinoma of unknown primary (CUP) is recognised as a distinct favourable subtype in the European Society of Medical Oncology (ESMO) classification. There is broad consensus that these patients are candidates for local ablative treatment strategies with surgery and/or radiotherapy, but data on their outcomes are scarce., Patients and Methods: In this study, we have addressed the prospects of cure and prognostic factors in a retrospective cohort of 63 patients who were eligible for local treatment at our centre., Results: Median event-free (EFS) and overall survival (OS) were 15.6 months and 52.5 months, respectively. Of 61 patients who received local treatment, 20 (32.8%) remained event-free over a median follow-up of 28 months. Baseline clinical parameters including affected organ, number, volume and histology of metastases had no significant impact on prognosis, whereas deleterious TP53 mutations and DNA copy number loss emerged as independent adverse risk factors with respect to EFS. Surgical treatment was associated with improved OS as compared to radiation-based therapy., Conclusion: Our study advocates to pursue localised treatment with surgery and/or radiotherapy whenever feasible and implies that genetic parameters might additionally determine the clinical course of single-site CUP patients., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: VE: advisory board and lecture fees from AstraZeneca and Thermo Fisher. AS: Advisory Board and/or Speaker's Bureau: AIGnostics, Astra Zeneca, Bayer, BMS, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher; Research Grants: Bayer, BMS, Chugai, Incyte. AK and TB work as study oncologists for the CUPISCO trial which is sponsored by Roche and have received reimbursement for study-related travels as well as remuneration for their work as study oncologists for the benefit of their employer. AK has also received research funding from BMS. The remaining authors have no conflict of interest., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF